Project Grant R01AI189552

Award Date 1/14/25
Completion Date 12/31/29
Dollars Obligated $729K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616 to support research on how the human adenovirus manipulates host cell processes to facilitate viral infection. The primary objectives are to investigate the role of arginine methylation, a post-translational modification, in regulating host RNA-binding proteins (RBPs) and how the viral 100kDa protein...
This $986,387 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to identify cellular proteins associated with adeno-associated virus (AAV) genomes. The goal is to improve understanding of the cellular factors that interact with AAV genomes to facilitate gene expression, DNA replication, genome encapsidation, and vector transduction. The researchers will employ a novel proteomics technology to...
This $284,331 federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize the stability and potential destabilization of gene therapy vectors based on adeno-associated virus (AAV) in human hepatocytes when challenged by natural virus infections. The key objectives are to (1) develop methods to track changes in AAV vector genome abundance and...
The federal Project Grant award R21AI188505 for $237,165.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the molecular mechanisms underlying the initiation of translation for picornaviruses, a group of important human pathogens. The research aims to identify the factors that enable ribosomal complexes to access sequestered viral initiation codons, establish...
This Project Grant award, valued at $582,618.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of the project is to determine the mechanisms by which RNA N6-methyladenosine (m6A) and pseudouridine (Ψ) modifications modulate SARS-CoV-2 replication, gene expression, immunity, and pathogenesis. The project involves using CRISPR-Cas9 to knock out host RNA m6A methyltransferases...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve the understanding of how antibodies can control viral infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The $318,085 award, effective from December 23, 2024 to...
The federal Project Grant award F32AI183625, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define how the cellular protein SLBP (stem-loop binding protein) promotes the infectivity of human cytomegalovirus (HCMV). The $290,132 award, with a period of performance from November 30, 2024 to June 1, 2026, aims to identify and characterize the novel, pro-viral function of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $228,435 to the University of California, Irvine to investigate the role of the APOBEC3B enzyme in the innate immune response against RNA viruses. The research aims to 1) explain how APOBEC3B modulates the PKR signaling pathway to promote translation arrest, and 2) determine whether APOBEC3B can suppress RNA virus...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to determine the molecular, cellular, and evolutionary mechanisms by which certain viruses evade or co-opt innate immune peptides called defensins to enhance their infectivity. The $148,568 award, spanning from November 2024 to June 2026, will be conducted at the University of Washington. The research aims...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totaling $734,184, will support research into the mechanisms of parainfluenza virus genome replication. The primary objectives of this 5-year award are to: 1) conduct structure-guided analysis of the parainfluenza virus polymerase complex to identify key molecular features and determine how transcription and replication...

The federal Project Grant award R01AI189552, totaling $729,006.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). This grant supports research to investigate how the adenovirus manipulates host RNA binding proteins (RBPs) to exploit cellular RNA processing pathways and overcome host defenses. The research aims to define the mechanisms by which modulation of RBP methylation promotes adenovirus infection through changes to splicing and RNA processing, as well as examine viral evasion of cytoplasmic granules and the impact of manipulating host responses. The award is held by the Children's Hospital of Philadelphia Research Institute, a leading pediatric medical research institution, and the research will employ innovative technologies to study changes in RNA-protein complexes mediated by RBP modification during adenovirus infection. The findings from this project are expected to provide fundamental knowledge of virus-host interactions and identify potential new antiviral therapeutic targets.

Generated 6/17/25, 1:43 AM